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Background
An important problem in treatment-experienced HIV-pos-
itive patients is resistance. It could be difficult to find a
suitable regimen for heavily pre-treated patients.
Methods
In heavily pre-treated patients in whom we found detect-
able viral load under adjusted antiretroviral treatment,
according to result of resistance and tropism test, we tried
a new therapeutic line as combination: MK-0518 +
boosted TMC-114 + TMC-125 and maraviroc (all patients
were naive to this combination). We measured viral load
(Abbot Real time) (<40 copies/ml = undetectable) and
CD4 count at day 1, week 3, week 8, week 12 and week 24.
Summary of results
Among six patients who received this combination there
are three men and three women. Mean age is 48.7 years (r
= 46–50). They have already received 8–19 therapeutic
lines (mean = 11), as well as 11–18 (mean = 14) mole-
cules. Mean viral load at day 1 was 35,638 copies/ml =
4.55 log(r = 80–87,100) which is reduced to 76 copies/ml
= 1.88 log at week 3, 166 copies/ml = 2.22 log at week 8
and less than 40 copies/ml = 1.6 log = undetectable at
week 12. At week 3, 3/6 patients found undetectable viral
load and at week 8, 5/6 found undetectable viral load and
at week 12 all six patients in therapeutic failure found
undetectable viral load. CD4 count, which was 330 (r =
155–649) at day 1, increased to 390 at week 3 and 394 at
week 8. We did not find any adverse events in this group
of patients.
Conclusion
Combination of TMC-114/R, TMC-125, MK-0518 and
maraviroc can be a safe, good option in heavily pre-
treated CCR5-positive patients which can reduce viral
load 3–4 logs in 3 weeks and reach to undetectable viral
load in less than 12 weeks.
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